Anthropometric and body composition measurements were feasible to obtain in children with special needs. However, the reliability of these measures differs between non-standers and standers and should be considered when choosing appropriate measures.

No abstract

Favorable survival outcomes with CPX-351 vs conventional 7+3 and comparable safety in adults aged 60-75 years in the pivotal phase 3 trial (NCT01696084) led to the approval of CPX-351 for newly diagnosed therapy-related acute myeloid leukemia (tAML) or AML with myelodysplasia-related changes (AML MRC) in the US and Europe. However, the trial did not include patients aged <60 years, creating a data gap on the potential effectiveness in younger patients. The CPX-351 Real-world Effectiveness and SafeTy (CREST-UK; NCT05169307) study evaluated the use of CPX-351 in routine UK clinical practice in patients aged ≥18 years with newly diagnosed tAML or AML MRC.

Nutritionally complete gastrostomy feeds may be protective against vitamin D deficiency in the majority of children with special needs. We recommend that all children over 1 year of age receive 10 μg (400 IU) of vitamin D, as recommended by the Scientific Advisory Committee on Nutrition (SACN).